Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 282 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenocarcinoma of Rectum Clear all
Withdrawn Phase 2 Interventional

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

NCT00408772
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation
Biological · Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
View directory record Official record
Conditions
Colorectal Cancer
Interventions
everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 7, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional Results available

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

NCT03992456
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Panitumumab, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride
Biological · Other · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00006094
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
oxaliplatin, fluorouracil, external beam radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 7, 2026, 9:24 PM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

NCT00021281
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, semaxanib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00006001
View directory record Official record
Conditions
Colorectal Cancer
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

NCT00025350
View directory record Official record
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

NCT00027534
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
TRICOM-CEA(6D)
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Midostaurin (PKC412) for Locally Advanced Rectal Cancer

NCT01282502
View directory record Official record
Conditions
Adenocarcinoma of the Rectum
Interventions
Midostaurin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

NCT00019786
View directory record Official record
Conditions
Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer, Neuroendocrine Carcinoma
Interventions
isolated perfusion, melphalan, conventional surgery
Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 7, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

NCT04808323
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation, Cohort B: Dose Escalation Radiation, Cohort C: Dose Escalation Radiation, FOLFOX
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Not applicable Interventional

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

NCT05526079
View directory record Official record
Conditions
Rectal Cancer
Interventions
Watchfuf waiting
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 7, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional

Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer

NCT00967655
View directory record Official record
Conditions
Colorectal Cancer
Interventions
panitumumab, capecitabine, irinotecan hydrochloride, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Loma Linda Oncology Medical Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT03297710
View directory record Official record
Conditions
Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Quality-of-Life Assessment, Radiation Therapy, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Other · Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

NCT00611858
View directory record Official record
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-Fluorouracil, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 7, 2026, 9:24 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 7, 2026, 9:24 PM EDT
Recruiting Phase 2 Interventional

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07407647
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Biospecimen Collection, Prasterone, Survey Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

NCT00033306
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ixabepilone, Fluoropyrimidine, Irinotecan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 7, 2026, 9:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Young-Onset Colorectal Cancer

NCT02863107
View directory record Official record
Conditions
Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
Interventions
Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2030
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

NCT01111292
View directory record Official record
Conditions
Colon Carcinoma, Dysplasia in Crohn Disease, Low Grade Dysplasia in Ulcerative Colitis, Rectal Carcinoma
Interventions
Inositol, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

NCT00084773
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, fluorouracil, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

NCT00656123
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Colon GVAX, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

NCT00911170
View directory record Official record
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 7, 2026, 9:24 PM EDT
Recruiting Phase 2 Interventional

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

NCT05672524
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma, Rectal Cancer
Interventions
Trastuzumab, Tucatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 7, 2026, 9:24 PM EDT